The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Thus far, Pfizer's obesity efforts have crashed and burned. Last year, the pharmaceutical giant threw in the towel on ...

The company expects to launch more than 20 pivotal late-stage trials this year.